Table 1.
Differences between women and men.
| Women (n = 273) | Men (n = 438) | p | |
|---|---|---|---|
| Demographics and medical history | |||
| Age, yrs (median, IQR) | 78 (76–81) | 78 (76–80) | 0.381 |
| Body mass index (median, IQR) | 22.7 (20.6–25.4) | 23.1 (20.9–25.4) | 0.427 |
| Diabetes mellitus, no. (%) | 96 (35.2) | 116 (26.5) | 0.014 |
| Hypertension, no. (%) | 217 (79.5) | 319 (72.8) | 0.050 |
| Atrial fibrillation, no. (%) | 30 (11.2) | 53 (12.3) | 0.656 |
| CKD ≥ 3 | 13 (4.8) | 26 (5.9) | 0.506 |
| Stroke, no. (%) | 32 (11.9) | 71 (16.5) | 0.098 |
| Previous chest pain, no. (%) | 181 (67.5) | 286 (66.2) | 0.716 |
| Previous PCI, no. (%) | 36 (13.5) | 78 (18.1) | 0.112 |
| Previous CABG, no. (%) | 3 (1.1) | 10 (2.3) | 0.255 |
| Current smoking, no. (%) | 14 (5.4) | 239 (56.5) | <0.001 |
| Clinical presentation | |||
| Hyperuricemia, no. (%) | 109 (39.9) | 142 (32.4) | 0.042 |
| Severe heart failure, no. (%) | 155 (56.8) | 201 (46.0) | 0.005 |
| STEMI, no. (%) | 56 (20.5) | 126 (28.8) | 0.014 |
| NSTE-ACS, no. (%) | 217 (79.5) | 312 (71.2) | 0.014 |
| Laboratory data | |||
| WBC, 109/L (mean ± SD) | 7.4 ± 3.3 | 7.2 ± 3.2 | 0.568 |
| Hemoglobin, g/L (mean ± SD) | 110.4 ± 18.3 | 121.8 ± 20.2 | <0.001 |
| Platelets, 109/L (mean ± SD) | 202.9 ± 64.9 | 174.3 ± 61.4 | <0.001 |
| Fasting glucose, mmol/l (median, IQR) | 6.0 (4.9–7.6) | 5.7 (4.8–7.1) | 0.181 |
| HbA1C, % (median, IQR) | 6.7 (6.0–7.4) | 6.1 (5.6–6.5) | 0.005 |
| ALT, u/l (median, IQR) | 17.5 (11.7–28.3) | 19.9 (13.6–33.5) | 0.012 |
| AST, u/l (median, IQR) | 22.6 (17.1–39.5) | 22.6 (17.8–49.9) | 0.579 |
| Albumin, g/L (mean ± SD) | 35.1 ± 4.5 | 35.1 ± 4.1 | 0.902 |
| Triglycerides, mmol/l (mean ± SD) | 1.6 ± 1.0 | 1.6 ± 4.2 | 0.960 |
| Total cholesterol, mmol/l (mean ± SD) | 4.1 ± 1.0 | 3.8 ± 0.9 | <0.001 |
| HDL-C, mmol/l (mean ± SD) | 1.1 ± 0.3 | 1.0 ± 0.3 | 0.002 |
| LDL-C, mmol/l (mean ± SD) | 2.4 ± 0.9 | 2.2 ± 0.8 | 0.002 |
| Creatinine, μmmol/l (mean ± SD) | 89.9 ± 54.1 | 124.4 ± 98.6 | <0.001 |
| Serum uric acid, μmmol/l (mean ± SD) | 349.2 ± 119.1 | 381.4 ± 110.1 | <0.001 |
| PT, sec (mean ± SD) | 13.7 ± 4.3 | 13.5 ± 2.8 | 0.674 |
| APTT, sec (mean ± SD) | 39.5 ± 14.4 | 41.4 ± 22.2 | 0.562 |
| CK-Mb, u/l (mean ± SD) | 35.0 ± 71.4 | 44.3 ± 119.0 | 0.266 |
| TnT, pg/ml (median, IQR) | 19.3 (9.7–603.3) | 33.2 (12.3–1461.0) | 0.141 |
| hs-CRP, mg/l (median, IQR) | 4.3 (1.3–23.2) | 5.1 (1.4–20.2) | 0.849 |
| NT-proBNP, pg/ml (median, IQR) | 935.9 (290.4–3082.5) | 1337.0 (394.9–3737.7) | 0.067 |
| EF, % (mean ± SD) | 53 ± 10.4 | 53 ± 10.9 | 0.460 |
| In-hospital management | |||
| Aspirin, no. (%) | 227 (83.2) | 376 (86.2) | 0.262 |
| Clopidogrel, no. (%) | 234 (86.0) | 391 (89.5) | 0.168 |
| ACEI/ARB, no. (%) | 168 (61.5) | 268 (61.2) | 0.925 |
| Beta blocker, no. (%) | 206 (75.5) | 306 (69.9) | 0.106 |
| Statin, no. (%) | 265 (97.8) | 422 (96.3) | 0.283 |
| Diuretic, no. (%) | 128 (47.6) | 210 (48.6) | 0.791 |
| PPI, no. (%) | 227 (84.4) | 340 (78.7) | 0.063 |
| IABP, no. (%) | 7 (2.6) | 18 (4.2) | 0.255 |
| Revascularization | 82 (30.0) | 174 (39.7) | 0.022 |
| In-hospital events | |||
| Heart failure, no. (%) | 42 (15.7) | 77 (17.9) | 0.458 |
| Bleeding, no. (%) | 22 (8.2) | 39 (9.1) | 0.706 |
| Ventricular tachycardia, no. (%) | 23 (8.6) | 36 (8.3) | 0.920 |
| Stroke, no. (%) | 5 (1.9) | 2 (0.5) | 0.071 |
| Death, no. (%) | 4 (3.5) | 8 (4.4) | 0.693 |
| One-year follow-up | |||
| Revascularization | 4 (1.6) | 7 (1.9) | 0.801 |
| Readmission, no. (%) | 96 (36.9) | 159 (39.9) | 0.436 |
| Stroke, no. (%) | 13 (5.2) | 18 (4.8) | 0.827 |
| Death, no. (%) | 40 (14.7) | 95 (21.7) | 0.020 |
STEMI: ST-segment elevation myocardial infarction; NSTE-ACS: non-ST-elevation acute coronary syndrome; WBC: white blood cell; ALT: glutamic-pyruvic transaminase; AST: glutamic-oxaloacetic transaminase; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; PT: prothrombin time; APTT: activated partial thromboplastin time; ACEI/ARB: angiotensin-converting enzyme inhibitors/angiotensin receptor blockers; PPI: proton pump inhibitor; IABP: intra-aortic balloon pump; CKD: chronic kidney disease; and CKD ≥ 3: estimated glomerular filtration rate (eGFR) < 60 mL/min per 1.73 m2.